Reported results
- Total operating expenses were $43.4 million for the three months ended September 30, 2026.
- Research and Development (R&D) expenses were $23.9 million for the three months ended September 30, 2026.
- General and Administrative (G&A) expenses were $19.4 million for the three months ended September 30, 2026.
- Net loss was $42.3 million, or $0.99 per basic and diluted share, for the three months ended September 30, 2026.
- Interest income was $1.1 million for the three months ended September 30, 2026.
Guidance
- Immunic expects that its cash and cash equivalents of $132.0 million will be sufficient to fund its operations into late 2027.
- Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials is expected in December 2026.
- First-patient-enrolled for the Phase 3 PROTECT-MS trial is expected in the first half of 2027.
- If ENSURE results are positive, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
